Log in

NASDAQ:SIEN - Sientra Stock Price, Forecast & News

$5.93
+0.05 (+0.85 %)
(As of 02/21/2020 07:24 AM ET)
Today's Range
$5.80
Now: $5.93
$6.00
50-Day Range
$5.88
MA: $7.20
$9.34
52-Week Range
$4.78
Now: $5.93
$11.92
Volume411,990 shs
Average Volume369,450 shs
Market Capitalization$293.42 million
P/E RatioN/A
Dividend YieldN/A
Beta0.36
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. Read More…

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SIEN
CUSIPN/A
Phone805-562-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$68.13 million
Book Value$2.34 per share

Profitability

Net Income$-82,630,000.00
Net Margins-143.76%

Miscellaneous

Employees259
Market Cap$293.42 million
Next Earnings Date3/10/2020 (Estimated)
OptionableOptionable

Receive SIEN News and Ratings via Email

Sign-up to receive the latest news and ratings for SIEN and its competitors with MarketBeat's FREE daily newsletter.


Sientra (NASDAQ:SIEN) Frequently Asked Questions

What is Sientra's stock symbol?

Sientra trades on the NASDAQ under the ticker symbol "SIEN."

How were Sientra's earnings last quarter?

Sientra Inc (NASDAQ:SIEN) released its quarterly earnings results on Thursday, November, 7th. The medical instruments supplier reported ($0.45) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.47) by $0.02. The medical instruments supplier earned $22.41 million during the quarter, compared to the consensus estimate of $20.05 million. Sientra had a negative return on equity of 122.95% and a negative net margin of 143.76%. The business's quarterly revenue was up 32.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.72) EPS. View Sientra's Earnings History.

When is Sientra's next earnings date?

Sientra is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Sientra.

What guidance has Sientra issued on next quarter's earnings?

Sientra updated its fourth quarter 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $23.2-23.2 million, compared to the consensus revenue estimate of $22.74 million.

What price target have analysts set for SIEN?

8 brokerages have issued 1-year price targets for Sientra's stock. Their forecasts range from $10.00 to $27.00. On average, they expect Sientra's stock price to reach $15.75 in the next year. This suggests a possible upside of 165.6% from the stock's current price. View Analyst Price Targets for Sientra.

What is the consensus analysts' recommendation for Sientra?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sientra in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sientra.

Has Sientra been receiving favorable news coverage?

News headlines about SIEN stock have been trending somewhat positive this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Sientra earned a media sentiment score of 1.3 on InfoTrie's scale. They also assigned headlines about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Sientra.

Who are some of Sientra's key competitors?

What other stocks do shareholders of Sientra own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sientra investors own include Genocea Biosciences (GNCA), Verizon Communications (VZ), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Regions Financial (RF), Baidu (BIDU), ChemoCentryx (CCXI), Idera Pharmaceuticals (IDRA), Opko Health (OPK) and AbbVie (ABBV).

Who are Sientra's key executives?

Sientra's management team includes the folowing people:
  • Mr. Jeffrey M. Nugent, Chairman & CEO (Age 72)
  • Mr. Charles Huiner, COO and Sr. VP of Corp. Devel. & Strategy (Age 48)
  • Mr. Keith J. Sullivan, Director & Advisor to MiraDry Bus. (Age 61)
  • Mr. Paul Sean Little, CFO, Sr. VP & Treasurer (Age 54)
  • Ms. Deborah Bettencourt, VP of Customer Experience & Corp. Admin.

Who are Sientra's major shareholders?

Sientra's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include UBS Group AG (4.84%), Schroder Investment Management Group (3.78%), Bamco Inc. NY (2.84%), Goldman Sachs Group Inc. (2.61%), Broadfin Capital LLC (2.60%) and UBS Asset Management Americas Inc. (2.16%). Company insiders that own Sientra stock include Jeffrey M Nugent, Keith J Sullivan, Patrick F Williams, Paul Sean Little, R Scott Greer and Timothy Haines. View Institutional Ownership Trends for Sientra.

Which major investors are selling Sientra stock?

SIEN stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, J. Goldman & Co LP, UBS Group AG, Barclays PLC, Bamco Inc. NY, Schroder Investment Management Group, Millrace Asset Group Inc. and Private Advisor Group LLC. View Insider Buying and Selling for Sientra.

Which major investors are buying Sientra stock?

SIEN stock was bought by a variety of institutional investors in the last quarter, including Monarch Partners Asset Management LLC, EAM Investors LLC, Assenagon Asset Management S.A., EAM Global Investors LLC, State Street Corp, Marshall Wace North America L.P., Granite Point Capital Management L.P. and Bank of New York Mellon Corp. Company insiders that have bought Sientra stock in the last two years include Jeffrey M Nugent, Keith J Sullivan, Patrick F Williams, Paul Sean Little, R Scott Greer and Timothy Haines. View Insider Buying and Selling for Sientra.

How do I buy shares of Sientra?

Shares of SIEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Sientra's stock price today?

One share of SIEN stock can currently be purchased for approximately $5.93.

How big of a company is Sientra?

Sientra has a market capitalization of $293.42 million and generates $68.13 million in revenue each year. The medical instruments supplier earns $-82,630,000.00 in net income (profit) each year or ($3.25) on an earnings per share basis. Sientra employs 259 workers across the globe.View Additional Information About Sientra.

What is Sientra's official website?

The official website for Sientra is http://www.sientra.com/.

How can I contact Sientra?

Sientra's mailing address is 420 SOUTH FAIRVIEW AVENUE SUITE 200, SANTA BARBARA CA, 93117. The medical instruments supplier can be reached via phone at 805-562-3500 or via email at [email protected]


MarketBeat Community Rating for Sientra (NASDAQ SIEN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  236 (Vote Outperform)
Underperform Votes:  297 (Vote Underperform)
Total Votes:  533
MarketBeat's community ratings are surveys of what our community members think about Sientra and other stocks. Vote "Outperform" if you believe SIEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SIEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Featured Article: Range Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel